1142 related articles for article (PubMed ID: 19541926)
41. The Impact of Breast Cancer Resistance Protein (BCRP/ABCG2) on Drug Transport Across Caco-2 Cell Monolayers.
Kawahara I; Nishikawa S; Yamamoto A; Kono Y; Fujita T
Drug Metab Dispos; 2020 Jun; 48(6):491-498. PubMed ID: 32193356
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of drug efflux transporter liabilities of darifenacin in cell culture models of the blood-brain and blood-ocular barriers.
Miller DW; Hinton M; Chen F
Neurourol Urodyn; 2011 Nov; 30(8):1633-8. PubMed ID: 21826715
[TBL] [Abstract][Full Text] [Related]
43. Effects of the antiretroviral drug 2'-deoxy-2'-β-fluoro-4'-azidocytidine (FNC) on P-gp, MRP2 and BCRP expressions and functions.
Liu Y; Wang Y; Peng Y; Liu B; Ma F; Jiang J; Wang Q; Chang J
Pharmazie; 2018 Sep; 73(9):503-507. PubMed ID: 30223932
[TBL] [Abstract][Full Text] [Related]
44. Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity.
Arias A; Rigalli JP; Villanueva SS; Ruiz ML; Luquita MG; Perdomo VG; Vore M; Catania VA; Mottino AD
Toxicology; 2014 Jun; 320():46-55. PubMed ID: 24685904
[TBL] [Abstract][Full Text] [Related]
45. Intestinal absorption mechanisms of araloside A in situ single-pass intestinal perfusion and in vitro Caco-2 cell model.
Yang H; Zhai B; Fan Y; Wang J; Sun J; Shi Y; Guo D
Biomed Pharmacother; 2018 Oct; 106():1563-1569. PubMed ID: 30119231
[TBL] [Abstract][Full Text] [Related]
46. Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.
Karibe T; Imaoka T; Abe K; Ando O
Drug Metab Dispos; 2018 May; 46(5):667-679. PubMed ID: 29358184
[TBL] [Abstract][Full Text] [Related]
47. Contribution of TRPV1 and multidrug resistance proteins in the permeation of capsaicin across different intestinal regions.
Duan L; Yan Y; Sun Y; Zhao B; Hu W; Li G
Int J Pharm; 2013 Mar; 445(1-2):134-40. PubMed ID: 23402980
[TBL] [Abstract][Full Text] [Related]
48. Transepithelial transport of fusariotoxin nivalenol: mediation of secretion by ABC transporters.
Tep J; Videmann B; Mazallon M; Balleydier S; Cavret S; Lecoeur S
Toxicol Lett; 2007 May; 170(3):248-58. PubMed ID: 17481833
[TBL] [Abstract][Full Text] [Related]
49. Effect of quercetin on the uptake and efflux of aristolochic acid I from Caco-2 cell monolayers.
Kimura O; Fujii Y; Haraguchi K; Ohta C; Koga N; Kato Y; Endo T
J Pharm Pharmacol; 2016 Jul; 68(7):883-9. PubMed ID: 27166429
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
Mukkavilli R; Jadhav G; Vangala S
Curr Pharm Biotechnol; 2017; 18(14):1151-1158. PubMed ID: 29521222
[TBL] [Abstract][Full Text] [Related]
51. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
Hoque MT; Kis O; De Rosa MF; Bendayan R
Antimicrob Agents Chemother; 2015 May; 59(5):2572-82. PubMed ID: 25691630
[TBL] [Abstract][Full Text] [Related]
52. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
[TBL] [Abstract][Full Text] [Related]
53. Characterization of the intestinal absorption of morroniside from Cornus officinalis Sieb. et Zucc via a Caco-2 cell monolayer model.
Xu R; Zhu H; Hu L; Yu B; Zhan X; Yuan Y; Zhou P
PLoS One; 2020; 15(5):e0227844. PubMed ID: 32470043
[TBL] [Abstract][Full Text] [Related]
54. Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.
Elsby R; Smith V; Fox L; Stresser D; Butters C; Sharma P; Surry DD
Xenobiotica; 2011 Sep; 41(9):764-83. PubMed ID: 21612343
[TBL] [Abstract][Full Text] [Related]
55. Interaction of Food Additives with Intestinal Efflux Transporters.
Sjöstedt N; Deng F; Rauvala O; Tepponen T; Kidron H
Mol Pharm; 2017 Nov; 14(11):3824-3833. PubMed ID: 28921988
[TBL] [Abstract][Full Text] [Related]
56. In vivo assessment of the impact of efflux transporter on oral drug absorption using portal vein-cannulated rats.
Matsuda Y; Konno Y; Hashimoto T; Nagai M; Taguchi T; Satsukawa M; Yamashita S
Drug Metab Dispos; 2013 Aug; 41(8):1514-21. PubMed ID: 23686319
[TBL] [Abstract][Full Text] [Related]
57. Caffeic acid inhibits the uptake of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by inducing the efflux transporters expression in Caco-2 cells.
Hong YJ; Yang SY; Nam MH; Koo YC; Lee KW
Biol Pharm Bull; 2015; 38(2):201-7. PubMed ID: 25399682
[TBL] [Abstract][Full Text] [Related]
58. Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra.
Cao J; Chen X; Liang J; Yu XQ; Xu AL; Chan E; Wei D; Huang M; Wen JY; Yu XY; Li XT; Sheu FS; Zhou SF
Drug Metab Dispos; 2007 Apr; 35(4):539-53. PubMed ID: 17220245
[TBL] [Abstract][Full Text] [Related]
59. Preclinical pharmacokinetics of PDE-310, a novel PDE4 inhibitor.
Song JS; Rho HJ; Park JS; Kim MS; Lee BH; Seo JW; Jeon DJ; Cheon HG; Ahn SH; Kwon KI; Bae MA
Drug Metab Pharmacokinet; 2011; 26(2):192-200. PubMed ID: 21206135
[TBL] [Abstract][Full Text] [Related]
60. Aconitum alkaloids, the major components of Aconitum species, affect expression of multidrug resistance-associated protein 2 and breast cancer resistance protein by activating the Nrf2-mediated signalling pathway.
Wu JJ; Zhu YF; Guo ZZ; Lou YM; He SG; Guan Y; Zhu LJ; Liu ZQ; Lu LL; Liu L
Phytomedicine; 2018 May; 44():87-97. PubMed ID: 29277460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
